BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 32597290)

  • 1. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
    Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health Care Burden Associated with Outpatient Opioid Use Following Inpatient or Outpatient Surgery.
    Brummett CM; England C; Evans-Shields J; Kong AM; Lew CR; Henriques C; Zimmerman NM; Pawasauskas J; Oderda G
    J Manag Care Spec Pharm; 2019 Sep; 25(9):973-983. PubMed ID: 31313621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database.
    Folkerts K; Petruski-Ivleva N; Kelly A; Fried L; Blankenburg M; Gay A; Kovesdy CP
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1506-1516. PubMed ID: 33251992
    [No Abstract]   [Full Text] [Related]  

  • 5. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Care Utilization and Economic Burden in Patients with Central Precocious Puberty: An Assessment of the Commercially Insured and Medicaid Populations.
    Klein K; Soliman AM; Bonafede M; Nelson JK; Grubb E
    J Manag Care Spec Pharm; 2019 Jul; 25(7):836-846. PubMed ID: 31232203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
    Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
    J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
    J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health Care Utilization and Costs Associated with Endometriosis Among Women with Medicaid Insurance.
    Soliman AM; Surrey ES; Bonafede M; Nelson JK; Vora JB; Agarwal SK
    J Manag Care Spec Pharm; 2019 May; 25(5):566-572. PubMed ID: 31039061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct Costs Incurred Among Women Undergoing Surgical Procedures to Treat Uterine Fibroids.
    Harrington A; Bonine NG; Banks E; Shih V; Stafkey-Mailey D; Fuldeore RM; Yue B; Ye JM; Ta JT; Gillard P
    J Manag Care Spec Pharm; 2020 Jan; 26(1-a Suppl):S2-S10. PubMed ID: 31958025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with Idiopathic Membranous Nephropathy: A Real-World Clinical and Economic Analysis of U.S. Claims Data.
    Nazareth TA; Kariburyo F; Kirkemo A; Xie L; Pavlova-Wolf A; Bartels-Peculis L; Vaidya N; Sim JJ
    J Manag Care Spec Pharm; 2019 Sep; 25(9):1011-1020. PubMed ID: 31283419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
    Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
    Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health Care Utilization and Economic Burdens of Hemochromatosis in the United States: A Population-Based Claims Study.
    Elsaid MI; John T; Li Y; Koduru S; Ali SZ; Catalano C; Narayanan N; Rustgi VK
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1377-1386. PubMed ID: 31778618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States.
    Udeze C; Evans KA; Yang Y; Lillehaugen T; Manjelievskaia J; Mujumdar U; Li N; Andemariam B
    Adv Ther; 2023 Aug; 40(8):3543-3558. PubMed ID: 37332020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
    Kang HA; Barner JC
    J Manag Care Spec Pharm; 2020 Nov; 26(11):1412-1422. PubMed ID: 33119448
    [No Abstract]   [Full Text] [Related]  

  • 16. Increased health care costs associated with new persistent opioid use after major surgery in opioid-naive patients.
    Brummett CM; Evans-Shields J; England C; Kong AM; Lew CR; Henriques C; Zimmerman NM; Sun EC
    J Manag Care Spec Pharm; 2021 Jun; 27(6):760-771. PubMed ID: 33624534
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.
    Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ
    J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Economic Burden of Nocturia on the U.S. Health Care System and Society: A National Health and Nutrition Examination Survey Analysis.
    Jhaveri J; Gauthier-Loiselle M; Gagnon-Sanschagrin P; Wu EQ
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1398-1408. PubMed ID: 31566054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic Burden of Illness in Adult Patients with Nocturia.
    Dmochowski R; Brucker BM; Cole E; Kawahara S; Pulicharam R; Burk C; Tung A; Hale D
    J Manag Care Spec Pharm; 2019 May; 25(5):593-604. PubMed ID: 30675816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United States.
    Blaiss MS; Meadows JA; Yu S; Robison DR; Hass SL; Norrett KE; Guerin A; Latremouille-Viau D; Tilles SA
    J Manag Care Spec Pharm; 2021 Apr; 27(4):516-527. PubMed ID: 33470880
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.